<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04868864</url>
  </required_header>
  <id_info>
    <org_study_id>13161</org_study_id>
    <nct_id>NCT04868864</nct_id>
  </id_info>
  <brief_title>The Ontario Multi-Regional Hospital COVID-19 Registry (COREG)- Recovery Trajectory Sub-study</brief_title>
  <acronym>COREG</acronym>
  <official_title>The Ontario Multi-Regional Hospital COVID-19 Registry (COREG)- Recovery Trajectory Sub-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiological and lung function recovery following Covid-19 infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose to conduct pulmonary LDCT imaging and physiological lung function&#xD;
      assessments, and combine this with detailed multi-regional hospitalization clinical data&#xD;
      collection on COVID-19 cases (COREG registry); to inform long-term pulmonary and&#xD;
      extra-pulmonary consequences and the recovery trajectory following COVID-19 infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>9 Months</target_duration>
  <primary_outcome>
    <measure>Pulmonary changes on LDCT Scan</measure>
    <time_frame>Through study completion, an average of 9 months</time_frame>
    <description>Identify pulmonary changes utilizing LDCT chest to characterize the pulmonary recovery trajectory of survivors of COVID-19.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DLCO</measure>
    <time_frame>Through study completion, an average of 9 months</time_frame>
    <description>Identify DLCO changes over time to characterize the pulmonary recovery trajectory of survivors of COVID-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLC</measure>
    <time_frame>Through study completion, an average of 9 months</time_frame>
    <description>Identify TLC changes over time to characterize the pulmonary recovery trajectory of survivors of COVID-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1</measure>
    <time_frame>Through study completion, an average of 9 months</time_frame>
    <description>Identify FEV1 changes over time to characterize the pulmonary recovery trajectory of survivors of COVID-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC</measure>
    <time_frame>Through study completion, an average of 9 months</time_frame>
    <description>Identify FVC changes over time to characterize the pulmonary recovery trajectory of survivors of COVID-19.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <condition>Sars-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Moderate to severe COVID-19 infection</arm_group_label>
    <description>COVID-19 patients with radiographic changes on CXR or CT which had not resolved or had persistent hypoxia due to COVID-19 at the time of discharge will be enrolled. All participants will undergo a LDCT and PFT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Persistent LDCT or PFT abnormalities</arm_group_label>
    <description>Participants with abnormalities on LDCT and or PFT will be invited to continue with a follow-up sub-study. This will involve follow up with repeated LDCT and PFT at subsequent time points to monitor and manage the abnormalities detected until the abnormalities fully resolve or to the last time point at 9 months of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT scan</intervention_name>
    <description>Non-enhanced LDCT scans of the thorax will be taken using standard technology on helical CT system</description>
    <arm_group_label>Moderate to severe COVID-19 infection</arm_group_label>
    <arm_group_label>Persistent LDCT or PFT abnormalities</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Pulmonary Function Test</intervention_name>
    <description>Standard pulmonary function testing will be conducted by trained pulmonary technologists following the American Thoracic Society standards</description>
    <arm_group_label>Moderate to severe COVID-19 infection</arm_group_label>
    <arm_group_label>Persistent LDCT or PFT abnormalities</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        COVID-19 patients discharged from hospitals with radiographic and clinical evidence of&#xD;
        COVID-19 pneumonia during hospitalization.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients discharged from hospital post COVID-19 infection who have radiographic and&#xD;
             clinical evidence of COVID-19 pneumonia during hospitalization.&#xD;
&#xD;
          -  Patients with evidence of unresolved radiographic changes or persistent hypoxemia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to comply with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mylinh Duong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mylinh Duong, MD</last_name>
    <phone>905 525-9140</phone>
    <email>duongmy@mcmaster.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Juravinski Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mylinh Duong, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 24, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>May 22, 2021</last_update_submitted>
  <last_update_submitted_qc>May 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hamilton Health Sciences Corporation</investigator_affiliation>
    <investigator_full_name>MyLinh Duong</investigator_full_name>
    <investigator_title>Professor Department of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

